Xultophy® 100/3.6 is a once-daily injectable to improve glycemic control for adults with type 2 diabetes as an adjunct to diet and exercise.1 Xultophy® 100/3.6 is a combination drug consisting of liraglutide, a long-acting glucagon-like peptide-1 receptor agonist, and insulin degludec, a long-acting basal insulin.1
Frequently asked questions about Xultophy® 100/3.6
ZUL-to-fye 100 3 point 6 is the correct pronunciation of Xultophy® 100/3.6.
Xultophy® 100/3.6 consists of two molecules that work together throughout the body to control blood sugar for a full 24 hours.
These components are insulin and GLP-1 RA. Insulin helps muscle, liver, and fat cells absorb and retain glucose from the bloodstream for energy. GLP-1 RA activity prevents processes that can cause sugar fluxes.
- In the gut, it slows down the rate at which glucose enters the bloodstream
- In the pancreas, it helps beta cells release insulin, but only when blood glucose is high
- When blood glucose is high, GLP-1 acts on alpha cells in the pancreas in ways that prevent the liver from releasing glucose
Xultophy® 100/3.6 has 2 starting doses.
Start patients naïve to basal insulin or a GLP-1 RA at 10 units.
10 units=10 units of insulin degludec and 0.36 mg liraglutide1
Start patients converting from basal insulin or a GLP-1 RA at 16 units.
16 units=16 units of insulin degludec and 0.58 mg liraglutide1
Therapy with basal insulin and GLP-1 RA should be discontinued prior to initiation of Xultophy® 100/3.6.1
Xultophy® 100/3.6 should be titrated every 3-4 days based on FPG.1 If patient is below FPG range, reduce 2 units. If patient is within the FPG target range, the dose should remain the same. If the patient is above the FPG target range, increase dose 2 units.1
The Xultophy® 100/3.6 pen is available from pharmacies in packs of 5. Each pen contains 300 units of Xultophy® 100/3.6.
Prior to use (until expiration date), Xultophy® 100/3.6 should be refrigerated between 36°F to 46°F (2°C – 8°C).
After first use (within 21 days), Xultophy® 100/3.6 can be left at room temperature between 59°F to 86°F (15°C – 30°C) or refrigerated at 36°F to 46°F (2°C – 8°C).1
Xultophy® 100/3.6 has a Boxed Warning. This warning, additional Important Safety Information, and side effects can be found in the Prescribing Information and Important Safety Information below.
Coverage and cost estimates for individual patients can be determined with the Cost Navigator at NovoCare.com. Enter a patient's information here to get started.